Bonnie C. Greenwood, PharmD, BCPS

Articles by Bonnie C. Greenwood, PharmD, BCPS

Cost-Benefit Analysis of Sacubitril/Valsartan in a Medicaid Population

ByAlan Gabot, PharmD,Pavel Lavitas, PharmD, BCPS,Rachel Bacon, PharmD, MPH,Thomas C. Pomfret, PharmD, MPH, BCPS,Mckenzie Taylor, PharmD, MS,Andrew Coelho, PharmD,Bonnie C. Greenwood, PharmD, BCPS,Caroline J. Alper, MD,Karen M. Clements, ScD,Kimberly Lenz, PharmD, MBA

July 13th 2022

The cost avoidance of heart failure–related hospitalizations and emergency department visits may outweigh the additional drug cost in Medicaid members adherent to sacubitril/valsartan.

Latest Updated Articles

Cost-Benefit Analysis of Sacubitril/Valsartan in a Medicaid Population
Published: July 13th 2022 | Updated:

Bonnie C. Greenwood, PharmD, BCPS

Articles by Bonnie C. Greenwood, PharmD, BCPS

Cost-Benefit Analysis of Sacubitril/Valsartan in a Medicaid Population

Latest Updated Articles

Trending on AJMC

Withdrawal of Aid Could Cause Millions of Lives Lost to HIV

EASO Recommends Semaglutide, Tirzepatide for First-Line Obesity Therapy

Recent FDA Approvals Expand Dermatology Options for Patients With Skin of Color

Stronger Primary Care, Oncology Partnerships May Improve Patient Outcomes: Mark Fendrick, MD

Opportunities and Obstacles Associated With the Medicare Diabetes Prevention Program